Skip to main content
NCBI home page
Current Therapeutic Research, Clinical and Experimental logoLink to Current Therapeutic Research, Clinical and Experimental
. 2005 Jan;66(1):48–65. doi: 10.1016/j.curtheres.2005.03.004

Increased risk for cardiovascular outcomes and effect of cholesterol-lowering pravastatin therapy in patients with diabetes mellitus in the pravastatin anti-atherosclerosis trial in the elderly (PATE)

Toshitsugu Ishikawa 1,**, Hideki Ito 2, Yasuyoshi Ouchi 3, Yasuo Ohashi 4, Yasushi Saito 5, Haruo Nakamura 6, Hajime Orimo 7, PATE Investigators *
PMCID: PMC3964557  PMID: 24672112

Abstract

Background:

The Pravastatin Anti-atherosclerosis Trial in the Elderly (PATE) was the first large-scale, prospective clinical trial to show that cholesterol-lowering therapy with pravastatin is effective in reducing the risk for cardiovascular events (CVEs) in elderly (aged ≥60 years) patients with hypercholesterolemia. PATE also included a subgroup of patients with diabetes mellitus (DM).

Objective:

The aim of this post hoc analysis was to assess the effects of lon-gtermpravastatin therapy on cardiovascular outcomes in the subgroup of patients with DM compared with a subgroup without it.

Methods:

PATE was conducted at 50 hospitals, universities, and clinics acrossJapan. Patients were randomly allocated to 1 of 2 treatment groups: low-dose pravastatin (5 mg PO QD; L group) or standard-lose pravastatin (in Japan, 10 mg PO QD; S group). Treatment was given for 3 to 5 years. Serum cholesterol levels were measured and the prevalence of CVEs was determined. The primary end point of the study was the S:L risk ratio for fatal or nonfatal CVEs. The secondary end point was the effect of diabetic patients' glycemic control on CVEs.

Results:

A total of 665 patients (527 women, 138 men; mean [SD] age, 72.8[5.7] years) were followed up for a mean of 3.9 years (range, 3–5 years). Among these, 199 patients had DM; 104 patients with DM were allocated to the L group and 95 to the S group. Four hundred sixty-six patients did not have DM (L group, 230 patients; S group, 236 patients). Overall, between 3 months and 3 years after the initiation of treatment, patients in the L group (mean dose, 4.5 mg/d) experienced reductions from baseline total cholesterol level of 11% to 13%. Those in the S group (mean dose, 8.3 mg/d) experienced reductions from baseline of 15% to 17%. Decreases in low-density lipoprotein cholesterol (LDL-C) levels were 17% to 20% and 23% to 26% in the L and S groups, respectively. Statistically similar reductions were noted between patients with DM and those without it in response to either dose. The DM subgroup experienced 32 CVEs (L group, 17; S group, 15) compared with 39 CVEs (L group, 25; S group, 14) in the subgroup without DM. The S:L CVE risk ratio (primary end point) was 0.94 (95% Cl, 0.46–1.92) in patients with DM and 0.54 (95% Cl, 0.28–1.05) in those without DM; the differences between the treatment groups were not statistically significant. The risk for CVEs in patients with DM whose glycosylated hemoglobin concentrations were <8.0% and ≥8.0% were, respectively, 1.87-fold (95% Cl, 1.09–3.20; P = 0.02) and 3.79-fold (95% Cl, 1.92–7.48; P < 0.01) higher than that in patients without DM.

Conclusions:

In this post hoc analysis of the effects of long-term cholesterol-loweringtherapy (low- and standard-dose pravastatin) on cardiovascular outcomes in elderly patients with DM, dose had no effect on the risk for CVEs in these patients as it did in those without DM. Poorer glycemic control in patients with DM was related to a higher risk for CVEs. The lack of pravastatin efficacy found in the subgroup with DM may have been attributable to the small differences in LDL-C levels found between the 2 treatment groups and/or the small sample size of the study.

Key words: PATE study, elderly patients, pravastatin, hyperlipidemia, diabetes mellitus, prospective interventional trial

Full Text

The Full Text of this article is available as a PDF (982.4 KB).

References

  • 1.Ito H., Ouchi Y., Ohashi Y. A comparison of low versus standard dose pravastatin therapy for the prevention of cardiovascular events in the elderly: The pravastatin anti-atherosclerosis trial in the elderly (PATE) J Atheroscler Thromb. 2001;8:33–44. doi: 10.5551/jat1994.8.33. [published correction appears in J Atheroscler Thromb. 2001;8:following 100] [DOI] [PubMed] [Google Scholar]
  • 2.Fujimoto W.Y., Leonetti D.L., Kinyoun J.L. Prevalence of complications among second-generation Japanese-American men with diabetes, impaired glucose tolerance, or normal glucose tolerance. Diabetes. 1987;36:730–739. doi: 10.2337/diab.36.6.730. [DOI] [PubMed] [Google Scholar]
  • 3.Diabetes mellitus: A major risk factor for cardiovascular disease. A joint editorial statement by the American Diabetes Association; The NationalHeart, Lung, and Blood Institute; The Juvenile Diabetes Foundation International; The National Institute of Diabetes and Digestive and Kidney Diseases; and The American Heart Association. Circulation. 1999;100:1132–1133. doi: 10.1161/01.cir.100.10.1132. [DOI] [PubMed] [Google Scholar]
  • 4.Laakso M., Lehto S. Epidemiology of risk factors for cardiovascular disease in diabetes and impaired glucose tolerance. Atherosclerosis. 1998;137:S65–S73. doi: 10.1016/s0021-9150(97)00314-6. (Suppl) [DOI] [PubMed] [Google Scholar]
  • 5.Uusitupa M.I., Niskanen L.K., Siitonen O. Ten-year cardiovascular mortality in relation to risk factors and abnormalities in lipoprotein composition in type 2 (non-insulindependent)diabetic and non-diabetic subjects. Diabetologia. 1993;36:1175–1184. doi: 10.1007/BF00401063. [DOI] [PubMed] [Google Scholar]
  • 6.Haffner S.M., Lehto S., Rönnemaa T. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339:229–234. doi: 10.1056/NEJM199807233390404. [DOI] [PubMed] [Google Scholar]
  • 7.Klein R. Hyperglycemia and microvascular and macrovascular disease in diabetes. Diabetes Care. 1995;18:258–268. doi: 10.2337/diacare.18.2.258. [DOI] [PubMed] [Google Scholar]
  • 8.Turner R.C., Millns H., Neil H.A. Risk factors for coronary artery disease in noninsulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23) BMJ. 1998;316:823–828. doi: 10.1136/bmj.316.7134.823. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Tominaga M., Eguchi H., Manaka H., Funagata Diabetes Study Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. Diabetes Care. 1999;22:920–924. doi: 10.2337/diacare.22.6.920. [DOI] [PubMed] [Google Scholar]
  • 10.Rodriguez B.L., Curb J.D., Burchfiel C.M., Honolulu Heart Program Impaired glucose tolerance, diabetes, and cardiovascular disease risk factor profiles in the elderly. Diabetes Care. 1996;19:587–590. doi: 10.2337/diacare.19.6.587. [DOI] [PubMed] [Google Scholar]
  • 11.DeFronzo R.A., Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care. 1991;14:173–194. doi: 10.2337/diacare.14.3.173. [DOI] [PubMed] [Google Scholar]
  • 12.Grundy S.M. Hypertriglyceridemia, insulin resistance, and the metabolic syndrome. Am J Cardiol. 1999;83:25F–29F. doi: 10.1016/s0002-9149(99)00211-8. [DOI] [PubMed] [Google Scholar]
  • 13.Enas E.A. Triglycerides and small, dense low-density lipoprotein. JAMA. 1998;280:1990–1991. doi: 10.1001/jama.280.23.1990. [DOI] [PubMed] [Google Scholar]
  • 14.Hulthe J., Bokemark L., Wikstrand J., Fagerberg B. The metabolic syndrome, LDL particle size, and atherosclerosis: The Atherosclerosis and Insulin Resistance (AIR) study. Arterioscler Thromb Vasc Biol. 2000;20:2140–2147. doi: 10.1161/01.atv.20.9.2140. [DOI] [PubMed] [Google Scholar]
  • 15.Festa A., D'Agostino R., Jr, Mykkänen L., Insulin Resistance Atherosclerosis Study LDL particle size in relation to insulin, proinsulin, and insulin sensitivity. Diabetes Care. 1999;22:1688–1693. doi: 10.2337/diacare.22.10.1688. [DOI] [PubMed] [Google Scholar]
  • 16.Cigolini M., Targher G., Seidell J.C. Relationships of plasminogen activator inhibitor-1 to anthropometry serum insulin, triglycerides and adipose tissue fatty acids in healthy men. Atherosclerosis. 1994;106:139–147. doi: 10.1016/0021-9150(94)90119-8. [DOI] [PubMed] [Google Scholar]
  • 17.Jokl R., Klein R.L., Lopes-Virella M.F., Colwell J.A. Release of platelet plasminogen activator inhibitor 1 in whole blood is increased in patients with type II diabetes. Diabetes Care. 1995;18:1150–1155. doi: 10.2337/diacare.18.8.1150. [DOI] [PubMed] [Google Scholar]
  • 18.Goldberg R.B., Mellies M.J., Sacks F.M., CARE Investigators Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarctionsurvivors with average cholesterol levels: Subgroup analyses in the cholesterol and recurrent events (CARE) trial. Circulation. 1998;98:2513–2519. doi: 10.1161/01.cir.98.23.2513. [DOI] [PubMed] [Google Scholar]
  • 19.Sacks F.M., Pfeffer M.A., Moye L. Rationale and design of a secondary prevention trial of lowering normal plasma cholesterol levels after acute myocardial infarction: The Cholesterol and Recurrent Events trial (CARE) Am J Cardiol. 1991;68:1436–1446. doi: 10.1016/0002-9149(91)90276-q. [published correction appears in Am J Cardiol. 1992;69:574] [DOI] [PubMed] [Google Scholar]
  • 20.Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S) Lancet. 1994;344:1383–1389. [PubMed] [Google Scholar]
  • 21.Haffner S.M., Alexander C.M., Cook T.J. Reduced coronary events in simvastatintreated patients with coronary heart disease and diabetes or impaired fasting glucose levels: Subgroup analyses in the Scandinavian Simvastatin Survival Study. Arch Intern Med. 1999;159:2661–2667. doi: 10.1001/archinte.159.22.2661. [DOI] [PubMed] [Google Scholar]
  • 22.Heart Protection Study Collaborative Group MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet. 2002;360:7–22. [Google Scholar]
  • 23.Kosaka K., Akanuma Y., Goto Y. Committee report for diagnosis for diabetes mellitus. J Jpn Diabetes Soc. 1982;25:859–866. [in Japanese] [Google Scholar]
  • 24.Friedewald W.T., Levy R.I., Frederickson D.S. Estimation of the concentration of lowdensity lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499–502. [PubMed] [Google Scholar]
  • 25.The 1988 Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 1988;148:1023–1038. [PubMed] [Google Scholar]
  • 26.Barringer T.A., III WOSCOPS. West of Scotland Coronary Prevention Group. Lancet. 1997;349:432–433. doi: 10.1016/s0140-6736(05)65059-3. [DOI] [PubMed] [Google Scholar]
  • 27.Frick M.H., Elo O., Haapa K. Helsinki Heart Study: Primary-prevention trial with gemfibrozil in middle-age men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med. 1987;317:1237–1245. doi: 10.1056/NEJM198711123172001. [DOI] [PubMed] [Google Scholar]
  • 28.Shepherd J., Blauw G.J., Murphy M.B. Pravastatin in elderly individuals at risk of cardiovascular disease (PROSPER): A randomised controlled trial. Lancet. 2002;360:1626–1630. doi: 10.1016/s0140-6736(02)11600-x. [DOI] [PubMed] [Google Scholar]
  • 29.Freeman D.J., Norrie J., Sattar N. Pravastatin and the development of diabetes mellitus: Evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation. 2001;103:357–362. doi: 10.1161/01.cir.103.3.357. [DOI] [PubMed] [Google Scholar]

Articles from Current Therapeutic Research, Clinical and Experimental are provided here courtesy of Elsevier

RESOURCES